263 related articles for article (PubMed ID: 32444405)
1. Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena.
Mukherjee M; Forero DF; Tran S; Boulay ME; Bertrand M; Bhalla A; Cherukat J; Al-Hayyan H; Ayoub A; Revill SD; Javkar T; Radford K; Kjarsgaard M; Huang C; Dvorkin-Gheva A; Ask K; Olivenstein R; Dendukuri N; Lemiere C; Boulet LP; Martin JG; Nair P
Eur Respir J; 2020 Oct; 56(4):. PubMed ID: 32444405
[TBL] [Abstract][Full Text] [Related]
2. Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab.
Mukherjee M; Aleman Paramo F; Kjarsgaard M; Salter B; Nair G; LaVigne N; Radford K; Sehmi R; Nair P
Am J Respir Crit Care Med; 2018 Jan; 197(1):38-46. PubMed ID: 28915080
[TBL] [Abstract][Full Text] [Related]
3. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma.
Sehmi R; Smith SG; Kjarsgaard M; Radford K; Boulet LP; Lemiere C; Prazma CM; Ortega H; Martin JG; Nair P
Clin Exp Allergy; 2016 Jun; 46(6):793-802. PubMed ID: 26685004
[TBL] [Abstract][Full Text] [Related]
4. Mepolizumab and eosinophil-mediated disease.
Walsh GM
Curr Med Chem; 2009; 16(36):4774-8. PubMed ID: 19929788
[TBL] [Abstract][Full Text] [Related]
5. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
6. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
Casale TB; Pacou M; Mesana L; Farge G; Sun SX; Castro M
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):122-130.e1. PubMed ID: 30217529
[TBL] [Abstract][Full Text] [Related]
7. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
[TBL] [Abstract][Full Text] [Related]
8. Super-responders to anti-IL-5/anti-IL-5R are characterised by high sputum eosinophil counts at baseline.
Gerday S; Graff S; Moermans C; Guissard F; Paulus V; Henket M; Louis R; Schleich F
Thorax; 2023 Nov; 78(11):1138-1141. PubMed ID: 37657926
[TBL] [Abstract][Full Text] [Related]
9. Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab.
Hillas G; Fouka E; Papaioannou AI
Expert Rev Respir Med; 2020 Apr; 14(4):353-365. PubMed ID: 31958239
[No Abstract] [Full Text] [Related]
10. Sputum autoantibodies in patients with severe eosinophilic asthma.
Mukherjee M; Bulir DC; Radford K; Kjarsgaard M; Huang CM; Jacobsen EA; Ochkur SI; Catuneanu A; Lamothe-Kipnes H; Mahony J; Lee JJ; Lacy P; Nair PK
J Allergy Clin Immunol; 2018 Apr; 141(4):1269-1279. PubMed ID: 28751233
[TBL] [Abstract][Full Text] [Related]
11. Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy.
Mukherjee M; Lim HF; Thomas S; Miller D; Kjarsgaard M; Tan B; Sehmi R; Khalidi N; Nair P
Allergy Asthma Clin Immunol; 2017; 13():2. PubMed ID: 28070196
[TBL] [Abstract][Full Text] [Related]
12. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials.
Bernstein JA; Virchow JC; Murphy K; Maspero JF; Jacobs J; Adir Y; Humbert M; Castro M; Marsteller DA; McElhattan J; Hickey L; Garin M; Vanlandingham R; Brusselle G
Lancet Respir Med; 2020 May; 8(5):461-474. PubMed ID: 32066536
[TBL] [Abstract][Full Text] [Related]
13. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.
Nair P; Pizzichini MM; Kjarsgaard M; Inman MD; Efthimiadis A; Pizzichini E; Hargreave FE; O'Byrne PM
N Engl J Med; 2009 Mar; 360(10):985-93. PubMed ID: 19264687
[TBL] [Abstract][Full Text] [Related]
14. Sputum hyaluronan and versican in severe eosinophilic asthma.
Ayars AG; Altman LC; Potter-Perigo S; Radford K; Wight TN; Nair P
Int Arch Allergy Immunol; 2013; 161(1):65-73. PubMed ID: 23257685
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation.
Nixon J; Newbold P; Mustelin T; Anderson GP; Kolbeck R
Pharmacol Ther; 2017 Jan; 169():57-77. PubMed ID: 27773786
[TBL] [Abstract][Full Text] [Related]
16. Exacerbations of Severe Asthma While on Anti-IL-5 Biologics.
Bhalla A; Zhao N; Rivas DD; Ho T; Perez de Llano L; Mukherjee M; Nair P
J Investig Allergol Clin Immunol; 2020; 30(5):307-316. PubMed ID: 32573459
[TBL] [Abstract][Full Text] [Related]
17. Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis.
Iftikhar IH; Schimmel M; Bender W; Swenson C; Amrol D
Lung; 2018 Oct; 196(5):517-530. PubMed ID: 30167841
[TBL] [Abstract][Full Text] [Related]
18. Anti-IL-5 in Mild Asthma Alters Rhinovirus-induced Macrophage, B-Cell, and Neutrophil Responses (MATERIAL). A Placebo-controlled, Double-Blind Study.
Sabogal Piñeros YS; Bal SM; van de Pol MA; Dierdorp BS; Dekker T; Dijkhuis A; Brinkman P; van der Sluijs KF; Zwinderman AH; Majoor CJ; Bonta PI; Ravanetti L; Sterk PJ; Lutter R
Am J Respir Crit Care Med; 2019 Feb; 199(4):508-517. PubMed ID: 30192638
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibodies for the treatment of refractory asthma.
Hambly N; Nair P
Curr Opin Pulm Med; 2014 Jan; 20(1):87-94. PubMed ID: 24275927
[TBL] [Abstract][Full Text] [Related]
20. Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response.
Drick N; Seeliger B; Welte T; Fuge J; Suhling H
BMC Pulm Med; 2018 Jul; 18(1):119. PubMed ID: 30021546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
